For AAV transduction, cerebral organoids (101 days) and cardiac organoids (11 days) were transduced with 1011 vg of eGFP transgene carrying AAV5 WT as negative control or with amended AAV ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

According to the study, published in the journal Human Gene Therapy, co-injection of immunodominant peptides from the transgene product, along with AAV8, modulates the immune response at all AAV ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) yesterday and set a price target of ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent ...

The investment firm said it believes TRACER alone should be a valuable asset, noting “initial novel AAV capsid candidates ...

AAV = Adeno-associated virus; Ad = Adenovirus; CIA = Collagen-induced arthritis; CTLA = Cytotoxic T-lymphocyte antigen; FADD = Fas-associated death domain; FAS-L = Fas ligand; FLS = Fibroblast ...